Retatrutide: The Next Generation GLP-1 Agonist

Research disclaimer: This article is for informational purposes only and does not constitute medical advice. Retatrutide is an investigational compound not yet approved for therapeutic use. Consult a qualified healthcare professional.

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that represents the next step in incretin-based therapy: a triple receptor agonist that simultaneously targets the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.

This builds directly on the dual agonism of tirzepatide (GLP-1 + GIP) by adding a third mechanism: glucagon receptor activation. Glucagon is typically associated with raising blood glucose — but at the doses produced by retatrutide's receptor activation, it increases energy expenditure and promotes hepatic fat clearance, adding a meaningful metabolic dimension to the compound's effects.

Why Triple Agonism?

Understanding why adding glucagon signalling might help requires brief context on each receptor:

GLP-1 receptor: Reduces appetite via central hypothalamic pathways, slows gastric emptying, enhances insulin secretion in a glucose-dependent manner. The workhorse of current approved therapies.

GIP receptor: Augments insulin secretion, modulates adipose tissue metabolism, and appears to improve GLP-1 receptor sensitivity. The dual-action mechanism of tirzepatide vs semaglutide already demonstrated that adding GIP activation improves efficacy over GLP-1 alone.

Glucagon receptor: When activated in the context of GLP-1 co-agonism, glucagon signalling increases thermogenesis (heat production), promotes fat breakdown in the liver (reducing hepatic steatosis), and increases basal metabolic rate. In isolation, glucagon would raise blood sugar — but when GLP-1 is simultaneously active, the insulin-stimulating and appetite-suppressing effects counteract hyperglycaemia, leaving the metabolic rate-enhancing effects in play.

The hypothesis is that adding glucagon activation to GLP-1/GIP dual agonism produces a unique metabolic profile: more weight loss, better liver fat reduction, and potentially more favourable lean mass preservation than GLP-1 or dual agonism alone.

Phase II Clinical Trial Results

In June 2023, Eli Lilly published Phase II results for retatrutide in The New England Journal of Medicine. The trial enrolled 338 adults with obesity or overweight (with at least one weight-related complication) and randomised them to receive subcutaneous retatrutide or placebo weekly for 24 weeks, with dose escalation.

Key findings at the highest dose (12 mg):

• Mean weight reduction of 17.5% at 24 weeks — comparable to or exceeding results seen at 24 weeks with semaglutide and tirzepatide at equivalent timepoints
• Nearly 100% of participants in the high-dose group lost at least 5% of body weight — an extraordinarily high response rate
• Significant reductions in liver fat by MRI — an effect attributed in part to the glucagon receptor component
• Dose-dependent reductions in HbA1c across groups, including non-diabetic participants

The published trial is available on PubMed: Triple hormone receptor agonist retatrutide for obesity and metabolic syndrome.

How Does It Compare to Existing Agents?

Direct head-to-head trials have not yet reported, but a rough Phase II comparison:

Agent	Mechanism	~24-week weight loss
Semaglutide 2.4 mg	GLP-1	~9–10%
Tirzepatide 15 mg	GLP-1 + GIP	~12–15%
Retatrutide 12 mg	GLP-1 + GIP + Glucagon	~17–18%

Phase III trials for retatrutide (the TRIUMPH programme) are ongoing, with results expected in 2025–2026. These will establish long-term efficacy, safety, and cardiovascular outcomes.

The Glucagon Safety Question

The inclusion of glucagon receptor activation raises natural questions about hyperglycaemia risk. The Phase II data was reassuring: blood glucose did not increase in any dose cohort, and the expected GLP-1-mediated insulin response appears to effectively counterbalance glucagon's glucose-raising effects.

Longer-term data from Phase III will be needed to confirm this balance holds across broader populations, including people with varying degrees of insulin resistance.

Potential Applications Beyond Obesity

The liver fat data from Phase II is noteworthy. Non-alcoholic fatty liver disease (NAFLD) and its more severe form NASH (non-alcoholic steatohepatitis) affect hundreds of millions globally and have few approved treatments. The glucagon receptor component's hepatic effects position retatrutide as a candidate for NASH trials, with separate research programmes under investigation.

There is also emerging research interest in GLP-1 agonists for neurodegenerative conditions, cardiovascular protection, and sleep apnoea. Whether triple agonism offers advantages over dual agonism in these contexts remains to be established.

Considerations for the Research Community

Retatrutide is not yet commercially available and is not approved for human use outside of clinical trials. Unlike approved agents like semaglutide, it cannot be sourced through standard prescribing pathways. Those working in metabolic research contexts should note that any available samples sourced from research peptide suppliers would require rigorous purity verification — RetaLABS is one such Australian supplier with purity documentation — the compound's triple-receptor activity means impurities or incorrect concentration have complex pharmacological implications.

Summary

Retatrutide represents the current frontier of incretin-based pharmacology. The Phase II data is striking, and if Phase III confirms these results with an acceptable long-term safety profile, it may establish a new efficacy benchmark in obesity medicine. The addition of glucagon receptor agonism adds a layer of metabolic complexity — and potential benefit — over existing dual agonists. It also raises the question of what ceiling exists for weight reduction through receptor agonism alone, and whether the next frontier lies in combination therapy, duration of action, or other mechanistic innovations entirely.

For those tracking this space from a hormone and metabolic optimisation perspective, understanding your baseline through a thorough blood panel is a sensible first step before engaging with any therapeutic intervention in this class.